Global Benzodiazepine Drugs Market Is Segmented By Product (Diazepam (Valium), Alprazolam (Xanax), Clonazepam (Klonopin), Clorazepate (Tranxene), Flurazepam (Dalmane), Lorazepam (Ativan), Midazolam (Versed), Oxazepam (Serax), Others), By Time of Action (Short-Acting, Ultra-short Acting, Long Acting), By Application (Anxiety disorders, Seizures, Insomnia, Alcohol Withdrawal, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis 2023 - 2030
Benzodiazepine Drugs Market Overview
[180 pages] Report on Global Benzodiazepine Drugs by DataM Intelligence estimates the market to grow at a CAGR of 2.29% during the forecast period 2023 - 2030. Benzodiazepine Drugs usage in treating diseases like anxiety, and insomnia is on the rise. North America is a dominating region in the global benzodiazepine drugs market. The competitive rivalry intensifies with Amneal Pharmaceuticals LLC, AdvaCare Pharma, Pfizer Inc and others operating in the market.
Benzodiazepines are a class of psychoactive drugs used to treat diseases like anxiety, insomnia, panic disorder, seizures, and alcohol withdrawal. Benzodiazepines appear to work by blocking the excessive activity of nerves in the brain and other areas in the central nervous system.
Benzodiazepine Drugs Market Scope
| Metrics | Details |
| Market CAGR | 2.29% |
| Segments Covered | By Product, By Time of Action, By Application, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Source: DataM Intelligence Analysis (2020)
Benzodiazepine Drugs Market Trends and Dynamics
The benzodiazepine drugs market growth is driven by the rise in research and development activities conducted by many pharmaceutical companies. In addition, increased patient awareness level, advances in the treatment options and adoption of a sedentary lifestyle are some of the impacting factors for benzodiazepine drugs.
Introducing novel drug treatments and routes of administration for epileptic seizures is expected to drive the global benzodiazepine drugs market during the forecast period.
Benzodiazepines (BZDs) are important agents in the management of epilepsy. They are the first choice of drugs for status epilepticus and seizures associated with post-anoxic insult and are also frequently used to treat febrile, acute repetitive and alcohol withdrawal seizures. Clinical advantages of these drugs include rapid onset of action, high efficacy rates and minimal toxicity. Benzodiazepines are used in various clinical situations because they have a broad spectrum of clinical activity and can be administered via several routes. For instance, In January 2020, the US FDA approved Neurelis, Inc drug Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in people with epilepsy six years of age and older.
For instance, UCB acquired Nayzilam from Proximagen in June 2018. In 2019, Nayzilam (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for epilepsy seizure clusters, was launched in the US.
Increasing the prevalence of mental disorders is expected to drive the global benzodiazepine drugs market during the forecast period.
Benzodiazepine drugs are administered as the first course of treatment regarding mental disorders like depression, bipolar disorder, schizophrenia, dementia, anxiety disorder, autism. The WHO, European Brain Council (EBC), and European College of Neuropsychopharmacology (ECNP) state that around 25% of the global population encounters mental disorders at least once in their lifetime. As per NSDUH (National Survey on Drug Use and Health), in 2017, close to 46.6 million adults suffered from mental disorders (up by 1.5% in 2010) in the US. So, it could infer that 18-20% of the people in the US suffer from mental disorders, which are expected to account for the largest share of the benzodiazepines market in the forecast period.
Side effects associated with the drugs coupled with misuse of drugs are the factors that hinder the growth of this market.
Common side effects of benzodiazepines are blurred vision, confusion, dizziness, drowsiness, decreased concentration, lack of coordination, nightmares, decreased libido, hypotension and respiratory depression are likely to hamper the overall demand for bezodiazepine drugs market.
Benzodiazepines (benzos) are commonly prescribed medications in the United States. In 2017, over 120 million benzodiazepine prescriptions were dispersed throughout the country as per the American Addiction Centers. Benzo belongs to a larger group of medications known as sedative-hypnotics and is commonly used to treat anxiety, panic disorder, muscle spasm, certain seizure disorders, and sleep disorders in rarer cases. Unfortunately, there is also a significant problem with benzodiazepine abuse in the U.S.
With continued use, both tolerance and physiological dependence on benzodiazepines may develop. As a result, people adopt more benzos to produce the desired effect and then continue taking them to avoid withdrawal. Though these aren’t the only contributing factors, both of these phenomena can contribute to ongoing, compulsive use of benzodiazepine abuse. In the United States, benzodiazepines are Schedule IV controlled substances, meaning they have known abuse potential and are available only by prescription
COVID-19 Impact Analysis on Benzodiazepine Drugs Market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Management of anxiety, delirium, and agitation cannot be neglected in coronavirus disease (COVID-19). Antipsychotics are usually used for the pharmacological management of delirium, confusion and behavioural disturbances. The concurrent use of treatments for COVID-19 and antipsychotics had eventual drug-drug interactions, which had a short-term negative impact on the market.
Benzodiazepine Drugs Market Segmentation Analysis
The anxiety disorders segment is expected to hold the largest share in this market segment
The anxiety segment is anticipated to account for a major share of the market during the forecast period. According to World Health Organization (WHO), the number of people living with anxiety disorders globally was 284 million in the year 2017, reflecting a 15.9% increase since 2005, as a result of population growth and ageing and estimated to be 3.6%. Anxiety disorders are more common among females than males (4.6% in females compared to 2.6% in males globally). As per the Anxiety and Depression Association of America, around 40 million adults of the US get affected by anxiety disorders every year, of which only 36.9% receive treatment, according to the Anxiety and Depression Association of America (ADAA). Thus, these factors are anticipated to increase the demand for benzodiazepine drugs market.
The diazepam segment is expected to hold the largest share in this market segment
Diazepam is likely to be the largest segment during the forecast period due to the new route of administration, strategic collaboration between companies for the development & commercialization of diazepam, and lower prescription cost for major diazepam factors attributed to the higher growth of the diazepam segment.
For instance, Valtoco a Neurelis, Inc product is a proprietary formulation of diazepam incorporating the unique combination of a vitamin E-based solution and Intravail absorption enhancement to obtain outstanding absorption, tolerability, and reliability in a nasal formulation and; it is delivered via a nasal formulation in a spray, being developed to manage children and adult patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity, also known as cluster seizures. The exact mechanism of action for diazepam is not fully understood, but it is thought to involve the potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor.
Moreover, the inorganic modes of expansion include technology and distribution agreements, product improvement, and partnerships. These moves are expected to give an impetus to the market in the forecast period. For instance – Xeris Pharmaceuticals, in Apr 2020, announced positive results out of their Phase 1b weight-based dosing study regarding diazepam intramuscular (IM) injection by using XeriSol technology.
Source: DataM Intelligence Analysis (2020)
Global Benzodiazepine Drugs Market Geographical Share
North America region holds the largest market share of the global benzodiazepine drugs market
North America is expected to dominate the global benzodiazepine drugs market due to more FDA approvals in that region. For instance, In February 2020, the United States Food and Drug Administration provided approval to Merck for its Belsomra drug in the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease. An article published by the National Center for Biotechnology Information, U.S. Library of Medicine in February 2018 stated that 50,000 to 150,000 people in the U.S. suffer from status epilepticus, with mortality estimated at less than 3% in children, but up to 30% in adults. For instance, Aquestive Therapeutics collaborated with Syneos Health, Covance, in 2020 completed Phase 3 trial of safety and tolerability study of chronic intermittent use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects with Epilepsy. An increase in the development of mental healthcare services and rising awareness towards anxiety disorders are responsible for the increase in the diagnosis of a generalized anxiety disorder (GAD). Growth in the geriatric population increases anxiety diagnosis rates in Mexico, thus directly boosting the demand for physiotherapies such as Cognitive Behavior Therapy (CBT) and generalized anxiety disorder (GAD) medication.
Source: DataM Intelligence Analysis (2020)
Benzodiazepine Drugs Market Companies and Competitive Landscape
The global benzodiazepine drugs market is moderately competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc, Bausch Health Companies, Inc, Teva Pharmaceutical Industries Ltd, AdvaCare Pharma, H.Lundbeck A/S, Amneal Pharmaceuticals LLC, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals (West-Ward Pharmaceuticals), Dash Pharmaceuticals LLC and Intas Pharmaceuticals Limited. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the software as a medical device globally. For instance, In September 2020, in Japan, Taisho Pharmaceutical Co., Ltd., initiated a phase II clinical trial to assess the efficacy of TS-142 in the treatment of insomnia. The trial is expected to complete in December 2021.
Key Companies to Watch
Pfizer Inc
Overview: Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The Company was established in 1849. It develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars.
Product Portfolio: The key product is XANAX (ALPRAZOLAM).
Why Purchase the Report?
- Visualize the composition of the benzodiazepine drugs market segmentation by product, time of action, application, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the benzodiazepine drugs market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of benzodiazepine drugs market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players.
The global benzodiazepine drugs market report would provide access to an approx. 40+ market data table, 45+ figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
